Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd covers the reporting period of March 19, 2026. The document serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate governance event and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is an insider transaction:
- Director: John Brancaccio, Non-Executive Director.
- Transaction: Acquisition of 5,000 ordinary shares.
- Price: $1.61 per share on NASDAQ.
- Total Holdings: The transaction brings his total holding to 31,201 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document solely references the attached news announcement (Exhibit 99.1) regarding the share acquisition.
Investor Verification Checklist
- Verify the total share count and ownership percentage of John Brancaccio post-transaction.
- Confirm the trading volume and price stability of OKYO Pharma shares on NASDAQ around March 19, 2026.
- Review the full text of Exhibit 99.1 for any additional context regarding the director's acquisition.